ArticleJACC. Advances2026
Peripartum Cardiomyopathy Genetic Screening Protocol and Registry: The PERCVD Trial in the Gulf South.
Article in JACC. Advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPeripartum cardiomyopathy (PPCM) is a pregnancy-associated form of systolic heart failure with high prevalence and mortality worldwide. It occurs in 1:1800 to 1:3500 births in the United States and disproportionately affects women in the Gulf South. Louisiana has the highest maternal mortality rate in the United States, yet no prospective registry exists to investigate the genetic basis of perinatal cardiovascular disorders, creating an urgent need for genetic assessment.
objectivesThe objective of the study was to establish the first PPCM prospective whole-genome sequencing and registry with future expansion to other perinatal cardiovascular disorders.
methodsThe PERCVD (Perinatal-Related Cardiovascular Disorder) Trial is being conducted at Woman's Hospital, Louisiana, in collaboration with The Lundquist Institute at Harbor-UCLA Medical Center. Individuals meeting PPCM-ESC 2019 diagnostic criteria (left ventricular ejection fraction <45% or fractional shortening <30% with chamber dilation, onset between the last month of pregnancy and five months postpartum) are enrolled in the study. Electronic informed consent is obtained through secure REDCap. Patients complete a virtual medical history visit, receive a kit for self-collected DNA, and complete health surveys. Genomic DNA extraction, whole-genome sequencing, and bioinformatic analysis will identify and annotate variants using American College of Medical Genetics and Genomics criteria. A PPCM genetic registry will catalog variant patterns to support future risk stratification.
resultsThe PERCVD Trial is enrolling patients, and clinical outcome data are not available. This protocol details eligibility criteria, study workflows, genetic testing algorithms, and follow-up design.
conclusionsThis trial is the first structured PPCM genetic screening program in the Gulf that will support precision cardiovascular care in maternal populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.